[CAS NO. 1338225-97-0] Doravirine
PRODUCTS SPECIFICATIONS [1338225-97-0]
DESCRIPTION [1338225-97-0]
Overview
| MDL | MFCD22417167 |
|---|---|
| Molecular Weight | 425.75 |
| Molecular Formula | C17H11ClF3N5O3 |
| SMILES | N#CC1=CC(OC2=C(C(F)(F)F)C=CN(CC(N3C)=NNC3=O)C2=O)=CC(Cl)=C1 |
5 Publications Citing Use of MCE
Summary
Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC 50 s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively [1] .
IC50 & Target
IC50: 4.5 nM (wild type reverse transcriptase ); 5.5 nM ( K103N reverse transcriptase ); 6.1 nM ( Y181C reverse transcriptase ) [1]
In Vitro
Selectivity and cytotoxicity studies confirmed that Doravirine is a highly specific nonnucleoside reverse transcriptase inhibitors with minimum off-target activities. In the presence of 50% normal human serum (NHS), Doravirine shows excellent potency in suppressing the replication of WT virus, with a 95% effective concentration ( EC 95 ) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC 95 95 of 43, 27, and 55 nM, respectively. Doravirine exhibits similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Administration of 50 mg Doravirine with a high-fat meal is associated with slight elevations in AUC time zero to infinity and C24 h with no change in C max [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02275780 | Merck Sharp & Dohme LLC |
HIV-1
|
December 1, 2014 | Phase 3 |
| NCT04097925 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Institut d´Investigació Biomèdica de Bellvitge|Hospital Universitari de Bellvitge |
HIV-1-infection
|
February 18, 2020 | Phase 2 |
| NCT02089659 | Merck Sharp & Dohme LLC |
HIV-1 Infection
|
March 26, 2014 | Phase 1 |
| NCT03272347 | Merck Sharp & Dohme LLC |
HIV-1 Infection
|
November 27, 2017 | Phase 2 |
| NCT04513626 | Centre de Recherches et d´Etude sur la Pathologie Tropicale et le Sida |
HIV Infections
|
September 15, 2020 | Phase 2 |
| NCT02549040 | Merck Sharp & Dohme LLC |
Human Immunodeficiency Virus-1 (HIV-1)
|
September 21, 2015 | Phase 1 |
| NCT04518228 | National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|Gilead Sciences|ViiV Healthcare|Merck Sharp & Dohme LLC |
HIV Infections|Tuberculosis
|
June 8, 2021 | |
| NCT05322083 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|MSD Pharmaceuticals LLC |
Virus-HIV
|
May 2022 | |
| NCT04892654 | Chelsea and Westminster NHS Foundation Trust |
HIV-1-infection
|
September 2021 | Phase 3 |
| NCT03894124 | Chelsea and Westminster NHS Foundation Trust|Merck Sharp & Dohme LLC|Imperial College London|University of Liverpool |
Human Immunodeficiency Virus
|
June 12, 2019 | Phase 1 |
| NCT04689737 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Merck Sharp & Dohme LLC |
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
|
March 20, 2021 | Phase 4 |
| NCT04636437 | AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
May 20, 2021 | Phase 4 |
| NCT04900974 | University of North Carolina, Chapel Hill|Merck Sharp & Dohme LLC |
HIV Infections|Pregnancy Related
|
June 9, 2022 | Phase 1 |
| NCT01632345 | Merck Sharp & Dohme LLC |
HIV Infections
|
October 12, 2012 | Phase 2 |
| NCT04079452 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Institut d´Investigació Biomèdica de Bellvitge|Hospital Universitari de Bellvitge |
HIV-1-infection
|
February 18, 2020 | Phase 3 |
| NCT03886701 | Walter K. Kraft|Merck Sharp & Dohme LLC|Thomas Jefferson University |
Latent Tuberculosis|Human Immunodeficiency Virus|Rifamycins Causing Adverse Effects in Therapeutic Use|Drug Interaction Potentiation
|
April 22, 2019 | Phase 1 |
| NCT04334551 | Clinique du Quartier Latin|Merck Frosst Canada Ltd. |
HIV Infections
|
June 23, 2020 | Phase 4 |
| NCT02715700 | Merck Sharp & Dohme LLC |
Human Immunodeficiency Virus (HIV) Infection
|
September 28, 2015 | Phase 1 |
| NCT04375800 | Merck Sharp & Dohme LLC |
Human Immunodeficiency Virus (HIV) Infection
|
February 3, 2021 | Phase 2 |
| NCT03332095 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections
|
July 2, 2018 | Phase 1|Phase 2 |
| NCT05202613 | University of Roma La Sapienza |
HIV
|
January 4, 2022 | |
| NCT05506605 | Fundacion Clinic per a la Recerca Biomédica |
HIV-1-infection
|
October 30, 2022 | Phase 4 |
| NCT04820933 | University of California, Los Angeles|Merck Sharp & Dohme LLC |
HIV I Infection|Cardiovascular Risk Factor|Lipid Metabolism Disorders
|
July 1, 2022 | Early Phase 1 |
| NCT02641067 | Merck Sharp & Dohme LLC |
Renal Impairment
|
January 26, 2016 | Phase 1 |
| NCT04538040 | Quest Clinical Research|Gilead Sciences |
HIV-1-infection
|
December 19, 2019 | Phase 4 |
| NCT04495348 | University of Colorado, Denver|Gilead Sciences |
HIV-1-infection|Weight Gain
|
October 22, 2020 | |
| NCT01466985 | Merck Sharp & Dohme LLC |
HIV-1 Infection
|
October 21, 2011 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 234.88 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3488 mL | 11.7440 mL | 23.4880 mL |
| 5 mM | 0.4698 mL | 2.3488 mL | 4.6976 mL |
| 10 mM | 0.2349 mL | 1.1744 mL | 2.3488 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution
References
- [1] Lai MT et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-63.
- [2] Anderson MS et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397-405.
Synonyms